The Immune Response to p53 in Breast Cancer Patients Is Directed against Immunodominant Epitopes Unrelated to the Mutational Hot Spot

Cancer Research

Volumn 52, Issue 22, 1992, Pages 6380-6384

  Lane, David ^e,f   Legros, Yann ^b   Soussi, Thierry ^b  

^a CEA SACLAY   (France)

^b Institut de Genetique Moleculaire ^*  (United Kingdom)

^c Oncologic Medicate ^*  (United States)

^d Laboratoire de Pharmacologic Experimental ^*  (United States)

^e SAINT LOUIS HOSPITAL   (France)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; PROTEIN P53;

AMINO TERMINAL SEQUENCE; ANTIBODY RESPONSE; ARTICLE; BREAST CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN STRUCTURE; SEROLOGY; TUMOR CELL;

ANTIBODIES, NEOPLASM; BREAST NEOPLASMS; FEMALE; GENES, P53; HUMAN; IMMUNODOMINANT EPITOPES; MUTATION; PEPTIDE FRAGMENTS; PROGNOSIS; PROTEIN P53; SUPPORT, NON-U.S. GOV'T;

EID: 0026442737     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Baker, S. J., Preisinger, A.C.M. Jessup, J. M., Paraskeva, C., Markowitz, S., Willson, J. K. V., Hamilton, S., and Vogelstein, B. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res., 50: 7717-7722, 1990.
2. Prosser, J., Thompson, A. L., Cranston, G., and Evans, H. J. Evidence that p53 behaves as a tumor suppressor gene in sporadic breast tumors. Oncogene, 5: 1573-1579, 1990.
3. Takahashi, T., Nau, M. M., Chiba, I., Birrer, M. J., Rosenberg, R. K., Vinocour, M., Levitt, M., Pass, H., Gazdar, A. F., and Minna, J. D. p53-a frequent target for genetic abnormalities in lung cancer. Science (Washington DC), 246: 491-494, 1989.
4. Gaidano, G., Ballerini, P., Gong, J. Z., Inghirami, G., Neri, A., Newcomb, E. W., Magrath, I. T., Knowles, D. M., and Dallafavera, R. p53 mutations in human lymphoid malignancies-association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA, 88: 5413-5417, 1991.
5. Miller, C. W., Aslo, A., Tsay, C., Slamon, D., Ishizaki, K., Toguchida, J., Yamamuro, T., Lampkin, B., and Koeffler, H. P. Frequency and structure of p53 rearrangements in human osteosarcoma. Cancer Res., 50: 7950-7954, 1990.
6. Mazars, R., Pujol, P., Maudelonde, T., Jeanteur, P., and Theillet, C. p53 mutations in ovarian cancer-a late event. Oncogene, 6: 1685-1690, 1991.
7. Kim, J. H., Takahashi, T., Chiba, I., Park, J. G., Birrer, M. J., Roh, J. K., Lee, H. D., Kim, J. P., Minna, J. D., and Gazdar, A. F. Occurrence of p53-gene abnormalities in gastric carcinoma tumors and cell lines. J. Natl. Cancer Inst., 83: 938-943, 1991.
8. Mashiyama, S., Murakami, Y., Yoshimoto, T., Sekiya, T., and Hayashi, K. Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene, 6:1313-1318, 1991.
9. Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischof T. F. Z., Tainsky, M. A., and Friend, S. H. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (Washington DC), 250: 1233-1238, 1990.
10. Srivastava, S., Zou, Z. Q., Pirollo, K., Blattner, W., and Chang, E. H. Germline transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature (Lond.), 348: 747-749, 1990.
11. Caron de Fromentel, C., and Soussi, T. pS3 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chrom. Cancer, 4:1-15, 1992.
12. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253:49–53, 1991.
13. Benchimol, S., Pim, D., and Crawford, L. Radioimmunoassay of the cellular protein p53 in mouse and human cell lines. EMBO J., 1:1055-1062, 1982.
14. Hall, P. A., Ray, A., Lemoine, N. R., Midgley, C. A., Krausz, T., and Lane, D. P. p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet, 338: 513, 1991.
15. Cattoretti, G., Rilke, F., Andrealo, S., D'amato, L., and Delia, D. p53 expression in breast cancer. Int. J. Cancer, 41:178-183, 1988.
16. Crawford, L. V., Pim, D. C., and Bulbrook, R. D. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J. Cancer, 30:403-408, 1982.
17. Caron de Fromentel, C., May-Levin, F., Mouriesse, H., Lemerle, J., Chandrasekaran, K., and May, P. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int. J. Cancer, 39: 185-189, 1987.
18. Davidoff, A. M., Iglehart, J. D., and Marks, J. R. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc. Natl. Acad. Sci. USA, 89: 3439-3442, 1992.
19. Soussi, T., Caron de Fromentel, C., Sttirzbecher, H. W., Ullrich, S., Jenkins, J., and May, P. Evolutionary conservation of the biochemical properties of pS3-specific interaction of Xenopus-laevis p53 with simian virus 40 large T-antigen and mammalian heat shock proteins-70. J. Virol., 63:3894-3901, 1989.
20. Towbin, H., Staehelin, R., and Gordon, J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA, 76:4350-4354, 1979.
21. Gillet, D., Ducancel, F., Pradel, E., Leonetti, M., Menez, A., and Boulain, J. C. Insertion of a disulfide-containing neurotoxin into E. coli alkaline phosphatase: the hybrid protein retains both Biological activities. Protein Eng., 5: 273-278, 1992.
22. Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hostetter, R., Cleary, K., Bigner, S. H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F. S., Weston, A., Modali, R., Harris, C. C., and Vogelstein, B. Mutations in the p53 gene occur in diverse human tumour types. Nature (Lond.), 342:705-708, 1989.
23. Banks, L., Matlashewsld, G., and Crawford, L. Isolation of human-/?55 specific monoclonal antibodies and their use in the studies of human p53 expression. Eur. J. Biochem., 159: 529-534, 1986.
24. Legros, Y., Lacabanne, V., D'Agay, M., Larsen, C., Pla, M., and Soussi, T. Isolation of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells. Bull. Cancer (Paris), in press, 1992.
25. Stephen, C. W., and Lane, D. P. Mutant conformation of p53-precise epitope mapping using a filamentous phage epitope library. J. Mol. Biol., 225: 577-583, 1992.
26. Gurney, E. G., Harrison, R. O., and Fenno, J. Monoclonal antibodies against simian virus 40 T antigens: evidence for distinct subclasses of large T antigen and for similarities among nonviral T antigens. J. Virol., 34:752-763,1980.
27. Midgley, C. A., Fisher, C. J., Bartek, J., Vojtesek, B., Lane, D., and Barnes, D. Analysis of p53 expression in human tumors: an antibody raised against human p53 expressed in E. coli. J. Cell Sci., 101: 183-189, 1992.
28. Davidoff, A. M., Kerns, B. J. M., Iglehart, J. D., and Marks, J. R. Maintenance of p53 alterations throughout breast cancer progression. Cancer Res., 51: 2605-2610, 1991.
29. Hinds, P. W., Finlay, C. A., Quartin, R. S., Baker, S. J., Fearon, E. R., Vogelstein, B., and Levine, A. J. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the “hot spot mutant phenotypes. Cell Growth & Differ., 1:571-580, 1990.
30. Soussi, T., Caron de Fromentel, C., and May, P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene, 5: 945-952, 1990.